ATE476431T1 - Piperidin- und azetidinderivate als glyt1- inhibitoren - Google Patents

Piperidin- und azetidinderivate als glyt1- inhibitoren

Info

Publication number
ATE476431T1
ATE476431T1 AT05821636T AT05821636T ATE476431T1 AT E476431 T1 ATE476431 T1 AT E476431T1 AT 05821636 T AT05821636 T AT 05821636T AT 05821636 T AT05821636 T AT 05821636T AT E476431 T1 ATE476431 T1 AT E476431T1
Authority
AT
Austria
Prior art keywords
piperidine
glyt1 inhibitors
azetidine derivatives
heteroaryl
glyt1
Prior art date
Application number
AT05821636T
Other languages
English (en)
Inventor
Wesley Peter Blackaby
Stephen Robert Fletcher
Andrew Jennings
Richard Thomas Lewis
Elizabeth Mary Naylor
Leslie Joseph Street
Joanne Thomson
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0427989A external-priority patent/GB0427989D0/en
Priority claimed from GB0427987A external-priority patent/GB0427987D0/en
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE476431T1 publication Critical patent/ATE476431T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT05821636T 2004-12-21 2005-12-21 Piperidin- und azetidinderivate als glyt1- inhibitoren ATE476431T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0427989A GB0427989D0 (en) 2004-12-21 2004-12-21 Heteroaromatic compounds
GB0427987A GB0427987D0 (en) 2004-12-21 2004-12-21 Therapeutic agents
PCT/GB2005/050258 WO2006067529A1 (en) 2004-12-21 2005-12-21 Piperidine and azetidine derivatives as glyt1 inhibitors

Publications (1)

Publication Number Publication Date
ATE476431T1 true ATE476431T1 (de) 2010-08-15

Family

ID=35949843

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05821636T ATE476431T1 (de) 2004-12-21 2005-12-21 Piperidin- und azetidinderivate als glyt1- inhibitoren

Country Status (8)

Country Link
US (1) US7655644B2 (de)
EP (1) EP1831201B1 (de)
JP (1) JP5055493B2 (de)
AT (1) ATE476431T1 (de)
AU (1) AU2005317846B2 (de)
CA (1) CA2592345C (de)
DE (1) DE602005022764D1 (de)
WO (1) WO2006067529A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2544981A1 (en) * 2003-11-12 2005-05-26 Merck & Co., Inc. 4-phenyl piperidine sulfonyl glycine transporter inhibitors
EP1729772B8 (de) * 2004-03-24 2017-04-19 Merck Sharp & Dohme Corp. Heteroaryl-piperidin-glycin-transporterhemmer
EP1745018A1 (de) * 2004-04-29 2007-01-24 Merck & Co., Inc. Inhibitoren des azetidinglycintransporters
WO2005107469A2 (en) * 2004-05-05 2005-11-17 Merck & Co., Inc. Morpholinyl piperidine glycine transporter inhibitors
DE602005024838D1 (en) 2004-09-30 2010-12-30 Merck Sharp & Dohme Cyclopropylpiperidinglycin-transporter-inhibitor
AU2005317846B2 (en) 2004-12-21 2011-12-08 Merck Sharp & Dohme Limited Piperidine and azetidine derivatives as GlyT1 inhibitors
JP5281395B2 (ja) * 2005-06-06 2013-09-04 メルク シャープ エンド ドーム リミテッド 統合失調症の治療用のｇｌｙｔ１阻害剤としてのシクロヘキサンスルホニル誘導体
CA2611376C (en) 2005-06-13 2013-09-10 Merck Sharp & Dohme Limited Therapeutic agents
WO2007053400A2 (en) 2005-10-28 2007-05-10 Merck & Co., Inc. Piperidine glycine transporter inhibitors
EP2381941A4 (de) * 2008-12-29 2012-08-01 Univ Vanderbilt 3.1.0-bicyclische glyt1-inhibitoren und verfahren zu ihrer herstellung und verwendung
EP2403337A4 (de) * 2009-03-03 2012-08-15 Univ Vanderbilt Alkylsulfonyl-2,3-dihydrospiro[inden-1,4'-piperidin]-analoge als glyt1-hemmer, verfahren zu ihrer herstellung sowie ihre verwendung zur behandlung psychiatrischer erkrankungen
US8436019B2 (en) * 2009-03-31 2013-05-07 Vanderbilt University Sulfonyl-piperidin-4-yl methylamine amide analogs as GlyT1 inhibitors, methods for making same, and use of same in treating psychiatric disorders
EP2413701A4 (de) * 2009-03-31 2012-10-03 Univ Vanderbilt Sulfonyl-azetidin-3-yl-methylamin-amidanaloga als glyt1-hemmer, verfahren zu ihrer herstellung sowie ihre verwendung zur behandlung psychiatrischer erkrankungen
US8883839B2 (en) * 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
TWI598325B (zh) * 2012-10-12 2017-09-11 Ｈ 朗德貝克公司 苯甲醯胺類
TW201427947A (zh) 2012-10-12 2014-07-16 Lundbeck & Co As H 環狀胺

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU765603C (en) 1998-04-14 2004-08-05 General Hospital Corporation, The Methods for treating neuropsychiatric disorders
CA2443672C (en) * 2001-04-12 2011-03-29 Pharmacopeia, Inc. Aryl and biaryl piperidines used as mch antagonists
US6664273B2 (en) * 2001-11-26 2003-12-16 Schering Corporation Piperidine based MCH antagonists for treatment of obesity and CNS disorders
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
CA2544981A1 (en) 2003-11-12 2005-05-26 Merck & Co., Inc. 4-phenyl piperidine sulfonyl glycine transporter inhibitors
WO2005080394A1 (en) * 2004-02-24 2005-09-01 Bioaxone Therapeutique Inc. 4-substituted piperidine derivatives
EP1729772B8 (de) * 2004-03-24 2017-04-19 Merck Sharp & Dohme Corp. Heteroaryl-piperidin-glycin-transporterhemmer
EP1745018A1 (de) 2004-04-29 2007-01-24 Merck & Co., Inc. Inhibitoren des azetidinglycintransporters
WO2005107469A2 (en) 2004-05-05 2005-11-17 Merck & Co., Inc. Morpholinyl piperidine glycine transporter inhibitors
DE602005024838D1 (en) * 2004-09-30 2010-12-30 Merck Sharp & Dohme Cyclopropylpiperidinglycin-transporter-inhibitor
AU2005317846B2 (en) 2004-12-21 2011-12-08 Merck Sharp & Dohme Limited Piperidine and azetidine derivatives as GlyT1 inhibitors
JP5281395B2 (ja) 2005-06-06 2013-09-04 メルク シャープ エンド ドーム リミテッド 統合失調症の治療用のｇｌｙｔ１阻害剤としてのシクロヘキサンスルホニル誘導体

Also Published As

Publication number Publication date
EP1831201B1 (de) 2010-08-04
US7655644B2 (en) 2010-02-02
JP2008524316A (ja) 2008-07-10
DE602005022764D1 (de) 2010-09-16
AU2005317846A1 (en) 2006-06-29
EP1831201A1 (de) 2007-09-12
CA2592345A1 (en) 2006-06-29
WO2006067529A1 (en) 2006-06-29
CA2592345C (en) 2013-09-24
JP5055493B2 (ja) 2012-10-24
US20080090796A1 (en) 2008-04-17
AU2005317846B2 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
NO20070529L (no) Kinazolindionderivater som parp-inhibitorer
NO20060665L (no) N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer
NO20060664L (no) N-substituerte benzimidazolyl C-kit inhibitorer
DE602005022764D1 (de) Piperidin- und azetidinderivate als glyt1-inhibitoren
NO20075059L (no) Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase
ATE402174T1 (de) Imidazopyridinderivate als kinaseinhibitoren
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
SE0401971D0 (sv) Piperidne derivatives
NZ533310A (en) Benzimidazoles useful as protein kinase inhibitors
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
NO20053794L (no) N-(1-benzyl-2-oxo-2-(1-piperazinyl) etyl)-1-piperidinkarboksamid-derivater og relaterte forbindelsers bruk som CGRP-antagonister for behandling av hodepine.
NO20085087L (no) Nye heterocykliske forbindelser
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
TW200716531A (en) Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia
IL183373A0 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
DE602006011752D1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301699D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
DE602005010744D1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
SE0300105D0 (sv) Diarylmethylidene piperdine derivatives, preparations thereof and uses thereof
WO2007020411A8 (en) Amide derivatives

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties